- Home
- JBLU vs NVCR Comparison
JBLU vs NVCR Comparison
Compare JBLU & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JBLU
- NVCR
- Stock Information
- Founded
- JBLU 1998
- NVCR 2000
- Country
- JBLU United States
- NVCR Switzerland
- Employees
- JBLU N/A
- NVCR N/A
- Industry
- JBLU Air Freight/Delivery Services
- NVCR Medical/Dental Instruments
- Sector
- JBLU Consumer Discretionary
- NVCR Health Care
- Exchange
- JBLU Nasdaq
- NVCR Nasdaq
- Market Cap
- JBLU 1.5B
- NVCR 1.3B
- IPO Year
- JBLU N/A
- NVCR 2015
- Fundamental
- Price
- JBLU $4.57
- NVCR $12.75
- Analyst Decision
- JBLU Sell
- NVCR Buy
- Analyst Count
- JBLU 8
- NVCR 7
- Target Price
- JBLU $5.04
- NVCR $28.64
- AVG Volume (30 Days)
- JBLU 17.6M
- NVCR 1.7M
- Earning Date
- JBLU 10-28-2025
- NVCR 10-30-2025
- Dividend Yield
- JBLU N/A
- NVCR N/A
- EPS Growth
- JBLU N/A
- NVCR N/A
- EPS
- JBLU N/A
- NVCR N/A
- Revenue
- JBLU $9,095,000,000.00
- NVCR $642,269,000.00
- Revenue This Year
- JBLU N/A
- NVCR $9.54
- Revenue Next Year
- JBLU $8.00
- NVCR $5.70
- P/E Ratio
- JBLU N/A
- NVCR N/A
- Revenue Growth
- JBLU N/A
- NVCR 11.17
- 52 Week Low
- JBLU $3.34
- NVCR $10.70
- 52 Week High
- JBLU $8.31
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- JBLU 58.13
- NVCR 57.16
- Support Level
- JBLU $4.00
- NVCR $11.38
- Resistance Level
- JBLU $4.29
- NVCR $11.63
- Average True Range (ATR)
- JBLU 0.19
- NVCR 0.51
- MACD
- JBLU 0.05
- NVCR 0.20
- Stochastic Oscillator
- JBLU 97.59
- NVCR 96.23
About JBLU JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The company has one operating segment, Air Transportation Services, which provides services in the United States, the Caribbean, Latin America, Canada, and Europe. The majority of revenue is generated from the Domestic & Canada segment.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.